• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Hiv Hcv Coinfected Patient

Hiv Hcv Coinfected Patient






Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    Hiv Hcv Coinfected Patient Hiv Hcv Coinfected Patient Presentation Transcript

    • Dental Management of the HIV & HCV Infected Patient dr shabeel pn
      • Comprehensive Dental Management of the HIV/HCV Infected Patient
      • Diagnosis and Treatment of Oral Manifestations of HIV/HCV
    • Comprehensive Dental Management of the HIV/HCV Infected Patient
    • Human Immunodeficiency Virus
      • First case discovered in retrospect in a British sailor that died in 1959
      • Approximately 1 million infected individuals in the US
      • Greatest number of new infections is in minority males and women
    • HIV Pathogenesis
      • Virus infects specific cells bearing CD4 membrane glycoprotein
      • HIV enters cell and its RNA is transcribed into DNA by reverse transcriptase enzyme
    • HIV Pathogenesis Cont.
      • Viral DNA becomes integrated into host-cell genome until host cell is activated
      • Reverse transcriptase, protease, integrase (and other) enzymes are needed to make new viral particles that then infect other cells
    • HIV Disease Progression
      • Good understanding of disease process, management of opportunistic infections and neoplastic conditions
      • Potential activators of HIV include concomitant infections of Cytomegalovirus, Hepatitis B virus, Herpes Simplex virus and Hepatitis C virus
      • Current treatments do not completely eliminate virus from body
    • Acute or Chronic Liver Disease
      • Infection with hepatitis A, B or C
      • Drug induced - alcohol, IV drug, other toxic chemical
    • Hepatitis C Virus
      • 170 million infected people worldwide
      • 4 million or 1.8% of US population is HCV+
      • Up to 70% of intravenous drug abusers are HCV+
      • 40-70% HCV infected persons develop chronic liver disease which is the leading cause of liver transplantation in US
    • Hepatitis C Virus
      • Dominant mode of transmission is blood-to blood contact
      • Risk groups:
      • Injection drug users
      • Body piercing, tattooing with contaminated equipment, blood products pre 1990
    • HCV Disease Progression
      • RNA virus, initial infection often asymptomatic, incubation period 2-26 weeks
      • Lots of mutations occur during viral replication thus the antibodies generated against HCV fail to neutralize mutant virus
      • Disease process not very well understood
    • HCV Disease Progression Cont.
      • When HCV viral replication occurs, liver enzymes ALT and AST are elevated
      • Cirrhosis is indicated with the liver function tests shows AST levels exceed ALT levels
      • Liver dysfunction can be asymptomatic, a thorough medical history and consultation with patient’s physician should be done to determine degree of liver dysfunction
    • Hepatitis C Virus Treatment
      • Limit alcohol consumption
      • Interferon alpha and ribavirin therapy
    • Hepatitis C Virus Therapy Side Effects:
      • Lowers resistance to infection, invasive dental procedures should be postponed if possible until therapy has ceased
      • May induce the onset of clinical depression, in addition chronic HCV infection decreases salivary gland function resulting in xerostomia
      • Can cause bone marrow suppression, neutrophil, platelet count should be monitored, PT and PTT should be assessed before invasive procedures
    • Dental Management of the HCV Infected Patient
      • Most significant problem for patients with cirrhosis is likelihood of prolonged bleeding due to lack of coagulation factors and thrombocytopenia
    • HIV/HCV Co-infection
      • Because HIV and HCV have similar routes of infection, HIV infected patients are at a risk for co-infection with HCV
      • Estimated 300,000 people co-infected with HIV and HCV
      • As HIV disease becomes more controlled, in HIV/HCV co-infected patients the most common cause of death in co-infected patients is complications of end-stage liver disease
    • HIV/HCV Co-infection
      • Early diagnosis, evaluation, and treatment of HCV should be considered for HIV+ patients because:
      • HCV: increases hepatotoxicity of HAART
      • increases risk of perinatal HIV transmission
      • may increase HIV progression, morbidity & mortality
        • HIV: increases hepatitis C viremia
        • can hinder diagnosis of HCV
      • increases HCV progression, morbidity & mortality
    • Patient Management
      • Hemostatic function
      • Susceptibility to infection
      • Drug actions/interactions
      • Ability to withstand treatment
    • Patient Management Cont.
      • Schedule appointments that cause minimal interruptions in eating or medication schedules, minimize stress
      • Be sympathetic, patients on a new regimen of medications may not feel well, may need to reschedule appointment, or may even forget an appt
    • Patient Management Cont.
      • More frequent recalls, possibly every 3-4 months
      • Stress prevention and use topical fluorides and topical antimicrobials to maintain optimal oral health
    • Provider Management
      • Take the time to do a thorough history and oral examination
      • Appropriate training to gain greater competence in identification, diagnosis and proper treatment of oral lesions
      • Access to a qualified oral pathology lab
      • Good follow-up system with patients
    • Treatment Planning - General
      • Comprehensive oral exam and review of medical history/condition
      • Modifications to care are similar to other medically compromised patients
      • Communicate with primary care provider on HIV and/or HCV disease progression
      • Principles of good oral health are the same for people with HIV/HCV
    • Treatment Planning - General Cont.
      • Consider more frequent recalls: every 3-4 months due to medication side effects, prevention and early detection of oral disease
      • Update medical history and markers of disease progression regularly: every 6 months
      • Aggressive in diagnosis and treatment of disease conditions
    • Treatment Planning - Restorative Considerations
      • Most principles are similar to HIV/HCV negative patients
      • Poor candidates for extensive restoration: rampant caries, reduced salivary flow, oral acidity, poorly controlled oral manifestations
      • Use of topical fluorides to prevent recurrent or root caries
    • Treatment Planning - Oral Surgery Considerations
      • Follow aseptic technique
      • Routine antibiotic use is contraindicated
      • Incidence of post-procedure complications is no greater that other populations, although patients with prolonged clotting time will experience delayed wound healing
    • Treatment Planning - OS Considerations Cont.
      • Have results of recent labs to assess hemostatic function and susceptibility to infection
      • Antibiotic pre-medication for prevention of SBE (AHA guidelines)
      • Neutropenia
      • Indwelling catheters
    • Treatment Planning - Periodontal Considerations
      • Frequent recalls
      • Adjunctive use of antimicrobials and chlorhexadine
    • Treatment Planning - Endodontic Considerations
      • Assess ability to withstand treatment
      • Endodontic treatment offers same benefits and risks as with other groups
      • Consider one-step endodontic therapy where appropriate
    • Patient Management
      • Hemostatic function
      • Susceptibility to infection
      • Drug actions/interactions
      • Ability to withstand treatment
    • Normal Lab Values
      • Platelets/ml 150-300K
      • Neutrophil cells/ml 2500-7000
      • Hemoglobin g/dl 14-18 male, 12-16 female
      • CD4 cells/ml 800-1500
    • Laboratory Markers of Liver Disease >750 250-750 0-250 U/L ALKALINE PHOSPHATASE 2000-30,000 400-2000 0-50U/L AST, SGOT 2000-30,000 400-2000 0-50 U/L ALT, SGPT 10-50 4-10 0.5-1.2 MG/DL SERUM BILIRUBIN HIGH ELEVATION MODERATE ELEVATION NORMAL
    • Bleeding Problems
      • Clotting factors are decreased in severe liver disease
      • Number and function of platelets may be decreased and factor replacement or transfusion may be required
      • Need PT/PTT for patient within 48 hrs of surgery
      • Elective surgery can be safely performed in patients with platelet counts greater than 60,000/mm 3 and PT/PTT of 0.8-1.5 INR
    • Advanced Liver Disease
      • Associated with altered drug metabolism
      • CNS dysfunction
      • Bleeding problems
      • Altered protein metabolism
    • Commonly Used Medications Metabolized in the Liver
      • Analgesics - acetaminophen, narcotics, ASA, NSAIDS
      • Anesthetics - lidocaine, procaine, mepivicaine
      • Antibiotics - erythromycin, tetracycline, metronidazole, clindamycin
    • Commonly Used Medications Metabolized in the Liver Cont.
      • Use extreme caution for patients with prolonged bleeding as ASA and NSAID can make it worse
      • Anesthetics - lidocaine has not been associated with any side effects when used appropriately
      • Antibiotics – metronidazole and tetracylcine metabolism may be severely impaired in patients with acute hepatitis or cirrhosis and should not be used
    • Diagnosis and Treatment of Oral Manifestations of HIV & HCV Infection
    • Fungal Disease Candidiasis- Candida albicans
    • Oral Candidiasis
      • Occurs in persons with poorly controlled diabetes, pregnancy, hormone imbalance, those receiving broad spectrum antibiotics, long term steroid treatment, cancer therapy and other immunocompromised individuals
      • Oral lesions may be erythematous, pseudomembranous, hyperplastic or angular cheilitis, DD-oral hairy leukoplakia
    • Candidiasis- Treatment
      • Topical therapy with nystatin or clotrimazole is effective. Treatment length is usually 10-14 days, follow up in 2 weeks
      • Clotrimazole 10mg, 1 tab 5x/day, dissolve slowly and swallow, 10 day treatement
      • Systemic treatment with fluconazole 100 mg/day for 10 days for oropharyngeal/r esophageal disease, follow up in 2 weeks
    • Bacterial Diseases
      • Linear Gingival Erythema
      • Necrotizing Ulcerative Gingivitis
      • Necrotizing Ulcerative Peridontitis
    • Periodontal Disease
      • Linear Gingival Erythema - profound erythema of the free gingival margin, responds poorly to treatment, usually asymptomatic.
      • Treatment - plaque removal and reinforce good oral hygiene, follow up in 2 weeks, frequent recalls, chlorhexadine
    • Periodontal Disease
      • HIV Necrotizing Gingivitis- erythema with ulceration and loss of interdental papillae.
      • Treatment - aggressive plaque removal, debridement, and reinforce good oral hygiene, follow up in 1 week, frequent recalls, chlorhexadine
    • Periodontal Disease Cont.
      • HIV Necrotizing Periodontitis - erythema, necrotic tissue and bone, halitosis, severe pain and loose teeth.
      • Treatment - removal of necrotic tissue, chlorhexadine rinsing with additional use of metronidazole, follow up in 3-4 days, frequent dental visits and reinforcement of good oral hygiene.
    • Viral Diseases
      • Hairy Leukoplakia
      • Herpetic simplex ulceration
      • Human Papillomatous growth
      • Kaposi sarcoma
      • Cytomegalovirus ulceration
    • Hairy Leukoplakia
      • Bilateral symmetrical white corrugated lesions on the lateral borders of the tongue as a result of reactivation of EBV
      • Usually asymptomatic, requires no treatment but podophyllum resin peels may be used
      • DD - tobacco associated leukoplakia, lichen planus, epithelial dysplasia, hyperplastic candidiasis
    • Herpes Simplex Ulceration
      • One or more small lesions usually on keratinized mucosa - hard palate, gingiva but may also be on vermilion border of lips and adjacent facial skin
      • Begins as painful multiple lesions and may coalesce to large, erosive ulceration
      • Treat with oral acyclovir for 10-14 days, follow up in 2 weeks
    • Kaposi Sarcoma
      • Reddish, purple flat or raised lesion usually on gingiva or hard palate. DD-hemangioma, hemorrhage. Biopsy shows neoplastic proliferation of endothelial cells
      • Inform patient’s medical provider to rule out KS in other locations
    • Kaposi Sarcoma Cont.
      • Treatment - intra-lesional injection with vinblastin (1x/week, 3-4 weeks), surgical excision, or radiation therapy, or both. Follow up every 4 weeks for 3 months
    • Cytomegalovirus Ulceration
      • Usually in severely immunocompromised individuals, CD4<50
      • Painful ulceration on any mucosal surface with nonindurated borders
    • Cytomegalovirus Ulceration Cont.
      • Biopsy lesion to confirm diagnosis
      • Inform medical doctor, ophthalmologic consultation to rule out CMV retinitis
      • Treatment - oral or IV gangciclovir, foscarnet, follow up in 1 week
    • Other Diseases
      • Lymphoma
      • Fibroma
      • Minor/ recurrent apthous ulceration
      • Major apthous ulceration
    • Lymphoma
      • Non-Hodgkin's- soft tissue swelling that is red and inflamed, painful and progresses rapidly
      • Diagnosis - biopsy
      • Inform medical provider to coordinate treatment, follow up 1 week
      • Treatment - systemic combination of chemotherapy, radiation and excision
    • Fibroma
      • Traumatically induced overgrowth of underlying connective tissue
      • May be calcified
      • Treatment - complete surgical removal, follow up 1-2 weeks for healing
    • Apthous Ulceration- Minor
      • Hormonal and medication (hydroxyurea and ddC/HIVID) induced
      • Nonkeratinized mucosa, cheeks, lips, soft palate, floor of mouth, ventral tongue
      • Less than 1cm, self-limiting, minor discomfort
      • Treatment - application of topical steriod ointment and/or topical anesthetic, follow up 10-14 days
    • Apthous Ulceration- Major
      • Hormonal and medication (hydroxyurea and ddC/HIVID) induced
      • Nonkeratinized mucosa, cheeks, lips, soft palate, floor of mouth, ventral tongue
      • Greater than 1cm, deep into connective tissue, dysphagia
      • Treatment - short course of systemic steroid (prednisone, 80mg/day for 7 days) or thalidomide, follow up 5-7 days
    • Salivary Gland Disease
      • Enlarged parotid gland with xerostomia
      • Treat associated xerostomia with pilocarpine (5mg TID), sugarless chewing gum, sugarless lemon drops, topical fluoride and frequent dental cleanings
    • Discussion Questions
    • Case Studies
    • Patient I
      • 35 year old HIV+ male presents to clinic for extraction of #1. Tooth is severely decayed but is asymptomatic, patient feels healthy.
      • Medical history reveals: PCP January 1995, esophageal candidiasis 1998, hepatitis C +.
      • Current medications: combivir(AZT & 3TC), crixivan, bactrim, ibuprofen, salogen and vitamins.
      • Lab values: platelets: 210K, neutrophil 1000 cells/ml, hemoglobin 8g/dl, viral load 250 copies/ml, CD4 186 cells/ml, liver enzymes WNL.
      • What is the proper course of action?
    • Patient II
      • 45 year old HIV+ male recently diagnosed with HIV presents for scaling and root planning. Patient is a little apprehensive but states that he is in good physical condition.
      • Medical history reveals: no history of any HIV-related illness, syphilis 1978 and gonorrhea 1980, artificial heart valve placed in June 1991.
      • Current medications: coumadin 5mg/day.
      • Lab values: platelets: 350K, neutrophils 600 cells/ml, hemoglobin 12g/dl, VL 8,000 copies/ml, CD4 380.
      • What is the proper course of action?
    • Patient III
      • 37 year old HIV+ female presents to clinic for extraction. Tooth is symptomatic, patient complains of lethargy and diarrhea.
      • Medical history reveals: PCP July 1995, IV drug use, “clean” since January 2000.
      • Current medications: tylenol and vitamins.
      • Lab values: platelets: 46K, neutrophils 700 cells, hemoglobin 14g/dl, viral load 40,000 copies/ml, CD4 45 cells/ml.
      • What is the proper course of action?
    • Patient IV
      • 17 year old HIV+ male presents for comprehensive dental care. After initial examination, you note that he needs #17 and #32 surgically extracted, prophylaxis of teeth, and several large restorations.
      • Medical history reveals: no opportunistic infections, recent diagnosis of HIV, HCV+.
      • Current medications: patient says he has chosen not to take any HIV medications, IFN, Ribavirin.
      • Lab values: platelets: 146K, neutrophils 1500 cells, hemoglobin 14g/dl, VL 800 copies/ml, CD4 455.
      • What is the proper course of action?
    • Patient V
      • 67 year old HIV+ female presents to clinic for full mouth extractions and fabrication of full upper and lower dentures. Eight root tips are present in each arch and all are asymptomatic. Patient has a current complaint of burning tongue and trouble swallowing. She says that she has had this before and her doctor gave her “some pink pills and it cleared it right up.”
      • Medical history reveals: diabetes 1987, PCP July 1998, cervical cancer September 1999, esophageal candidiasis march 2000 and April 2000.
    • Patient V Cont.
      • Current medications: Nelfinavir, HIVID, Ziagen, Bactrim, Insulin 2x/day
      • Lab Values: platelets: 85K, Neutrophils 700 cells/ml, hemoglobin 10g/dl, viral load 400,000 copies/ml, CD4 84 cells/ml, glucose 160mg/dl.
      • What is the proper course of action?
      • Log on to
      • www.hi-dentfinishingschool.blogspot.com